SimBioSys, Inc.

We are thrilled to announce a groundbreaking publication by our co-founder and Chief Scientific Officer, John Cole. His work on predictive modeling in oncology highlights innovative approaches to revolutionize cancer treatment and patient care. Key Highlights: • Predicting treatment outcomes • Integrating multi-omics data • Enhancing personalized treatment plans This publication showcases our commitment to advancing precision medicine through cutting-edge computational modeling. Congrats to John and the team for this remarkable achievement! #SimBioSys #Oncology #PrecisionMedicine #Research #Innovation #Healthcare

Congratulations to SimBioSys, Inc. scientists Jesse Bucksot, PhD, Katherine Ritchie, John C., and Daniel Cook for their groundbreaking work defining metabolic hallmarks across 34 cancer types, identified in 10,915 patients! The method, published in Cancers MDPI, provides biological interpretability to metabolic biomarkers, answering questions such as: • How does the growth rate of this tumor compare to those from other patients with the same cancer type? • What metabolic pathways deviate from expected values based on a large cohort of patients? • Are those pathways druggable? Read more here: https://lnkd.in/gGibTiZ8 #CancerResearch #HallmarksOfCancer #MetabolicModeling #PrecisionMedicine

We're excited to announce that our CEO and Co-Founder, Tushar Pandey, was recently featured on the LifeScience Success Podcast with Don Davis PhD, MBA Davis, PhD, MBA! In this episode, Tushar delves into the cutting-edge world of digital precision medicine in oncology and more: 🤖 The Power of AI: Discover how we're leveraging artificial intelligence to revolutionize cancer treatment. 💡 SimBioSys Innovation: Learn about the groundbreaking technology driving our mission to transform oncology. 🔮 Vision for the Future: Explore what's next for digital precision medicine and the biotech industry. 🌍 Act Local, Think Global: From Uganda to the USA, hear about Tushar's inspiring journey and its impact on SimBioSys’s commitment to ensuring healthcare equity for all. At @SimBioSys, we harness the power of AI and biophysical modeling to deliver personalized cancer treatment solutions. We extend our heartfelt thanks to Don Davis and the Life Science Success Podcast for featuring SimBioSys, allowing us to share our vision and the impact we're making in oncology. If you're interested in learning more, please have a listen! https://lnkd.in/giDijCAq #Simbiosys #Biotech #Innovation #AIinBiotech #DigitalPrecisionMedicine #Oncology #BiotechStartups #SciencePodcast #LifeScienceSuccess

🌟 We’re excited to share recent findings presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting the importance of preoperative breast MRI.   In this study, they reviewed clinical data from 102 women aged 22 to 40 who underwent surgery for breast cancer. They found that preoperative breast MRI identified additional cancer in nearly 25% of young women with breast cancer, emphasizing the critical role of advanced imaging in optimal patient care.     Read further: https://lnkd.in/eAi8yvAG    With TumorSight Viz, breast surgeons can unlock greater value from MRI images more easily. TumorSight Viz transforms traditional 2D images into 3D multi-angle views, using artificial intelligence to auto-segment tissues and provide key measurements. This technology optimizes patient-specific surgical plans, enhances decision-making, expands treatment options, and reduces unnecessary mastectomies. By offering oncologists more comprehensive information, TumorSight Viz empowers patients and improves surgical outcomes.    Learn more about the impact of preoperative MRI in breast cancer treatment and how TumorSight Viz is revolutionizing patient care: https://lnkd.in/gX5uv9Wd    #BreastCancerAwareness #CancerCare #HealthcareInnovation #TumorSight #SimBioSys #ASCO2024 #AIinHealthcare 

Olivia Munn's Breast Cancer Journey and TumorSight 🌟    We were deeply moved by Olivia Munn's recent story about her battle with breast cancer. Her journey underscores the critical importance of advanced diagnostics and comprehensive care.    Olivia's experience underscores the necessity of thorough risk assessment and timely intervention. The TumorSight digital precision medicine platform offers the tools needed for more personalized treatment planning, enhancing patient-doctor interactions and delivering precise, data-driven decision support for oncologists.    At SimBioSys, we're committed to revolutionizing cancer care with TumorSight. Our platform uses Artificial Intelligence and Computational Modeling to generate Spatial Biophysics that provide detailed, three-dimensional insights into tumor biology. This empowers healthcare professionals to make informed decisions, potentially reducing extensive surgeries and improving patient outcomes.    Learn more about how TumorSight is revolutionizing breast cancer care: https://simbiosys.com/    #BreastCancerAwareness #CancerCare #HealthcareInnovation #TumorSight #SimBioSys #OliviaMunn #AIinHealthcare 

We’re thrilled to share NVIDIA's recent highlight of SimBioSys as a Healthcare AI innovator! 🌟 NVIDIA recognized SimBioSys for being at the forefront of innovation, using Llama 3 to transform patient-doctor interactions, improve patient outcomes, and deliver more efficient healthcare solutions. NVIDIA’s state-of-the-art Llama 3 large language model is revolutionizing digital health and life sciences workflows. We are proud to leverage this groundbreaking advancement and be at the forefront of shaping the future of Precision Cancer Care! Discover more about how Llama 3 is driving digital health advancements: https://lnkd.in/gpGF89Dv #NVIDIA #MetaLlama3 #DigitalHealth #AI #HealthcareInnovation #SimBioSys #FutureOfHealthcare

In case you missed it, we recently presented six groundbreaking research posters at the SABC conference, demonstrating our dedication to advancing digital precision medicine solutions for cancer care. One standout poster, "Spatial PK-PD Model with Her2 Expression for Predicting Individual Tumor Response to TDM1," our PK/PD model was instrumental in predicting Individual Tumor response to T-DM1, showcasing its superior prognostic predictive abilities compared to gene expression of HER2 alone. Our team meticulously characterized the model's performance by developing logistics regression models, providing invaluable insights into tumor response to therapy over time. For more details on our innovative research and its potential impact, visit: https://lnkd.in/eWbreDMD #SABCConference #BreastCancerResearch #PrecisionMedicine #Innovation #CancerCare 

In case you missed it, we recently presented six groundbreaking research posters at the SABC conference, demonstrating our dedication to advancing digital precision medicine solutions for cancer care. One standout poster, "A Combined Radiomics and Tumor Erosion Model to Predict Post-neoadjuvant Therapy Tumor Characteristics for Personalized Breast Cancer Treatment," illustrates how our approach can aid breast cancer surgeons and patients in making critical decisions such as Breast Conservation vs. Mastectomy. By utilizing pre and post NA therapy tumor volume MRI scans from multiple institutions and leveraging advanced radiomic features and AI-generated tumor segmentation, we successfully predicted post Neoadjuvant (NA) therapy tumor volume. This represents a significant advancement in personalized breast cancer treatment. For more details on our innovative research and its potential impact, visit:  https://lnkd.in/eWbreDMD #SABCConference #BreastCancerResearch #PrecisionMedicine #Innovation #CancerCare 

We're excited to share that our CEO and Co-Founder, Tushar Pandey, was featured on The Biohub Podcast by Avetix Group!     In this episode, Tushar delves into the cutting-edge world of digital precision medicine in oncology and more: 🤖 The Power of AI: Discover how we're leveraging artificial intelligence to revolutionize cancer treatment.  💡 SimBioSys Innovation: Learn about the groundbreaking technology driving our mission to transform oncology.  🔮 Vision for the Future: Explore what's next for digital precision medicine and the biotech industry.  🌍 Act Local, Think Global: From Uganda to the USA, hear about Tushar's inspiring path and its impact on SimBioSys’s approach to ensuring healthcare equity for all.    At SimBioSys, we're committed to harnessing the power of AI and biophysical modeling to deliver personalized cancer treatment solutions. A huge thank you to The Biohub Podcast for featuring SimBioSys so we can share our vision and the impact we're making in oncology more broadly. Please have a listen if you’re interested in learning more! #Simbiosys #BioHub #Biotech #Innovation #AIinBiotech #DigitalPrecisionMedicine #Oncology #BiotechStartups #SciencePodcast Listen now:  https://lnkd.in/g3WuYb9z  https://lnkd.in/grEjuCwr 

We're thrilled to share some wisdom from the esteemed Dr. Christine Teal, Director of Breast Care Center and Chief of Breast Surgery at The George Washington University Medical Center. As a renowned co-author of "No Longer Radical," Dr. Teal brings unparalleled expertise to the field of breast cancer care. Her insights shed light on the importance of patient-centered treatment decisions. We're thrilled to have Dr. Teal's support and value her expertise, as we continue to display our commitment to redefining precision medicine and revolutionizing patient care. #BreastCancerAwareness #PatientCenteredCare #TumorSightViz #InnovationInHealthcare